肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Blood：阿扎胞苷联合化疗药物治疗白血病患儿的效果和安全性评估。

2018-01-18 MedSci MedSci原创

阿扎胞苷甲基转移酶抑制剂化疗白血病
关注

越来越多的证据表明DNA过度异常甲基化与白血病发生、化疗耐药和复发相关。DNA甲基转移酶抑制剂，如阿扎胞苷和地西他滨，已经证实在体外可逆转耐药性和原发性白血病细胞对细胞毒性药物的敏感性。现有研究人员进行I期临床试验首次对阿扎胞苷联合化疗药物用于复发性/难治性白血病患儿的效果和安全性进行评估。招募了14位患者（12位急性髓性白血病[AML]患者，2位急性淋巴细胞白血病[ALL]患者）。所有患者接受阿

越来越多的证据表明DNA过度异常甲基化与白血病发生、化疗耐药和复发相关。DNA甲基转移酶抑制剂，如阿扎胞苷和地西他滨，已经证实在体外可逆转耐药性和原发性白血病细胞对细胞毒性药物的敏感性。现有研究人员进行I期临床试验首次对阿扎胞苷联合化疗药物用于复发性/难治性白血病患儿的效果和安全性进行评估。

招募了14位患者（12位急性髓性白血病[AML]患者，2位急性淋巴细胞白血病[ALL]患者）。所有患者接受阿扎胞苷 75mg/m2/天 皮下注射 连用5天，随后予以氟达拉滨 30mg/m2/天和阿糖胞苷2mg/m2/天 静脉用药 连用5天。患者在本研究前治疗的中位次数2次（1-5）。最常见的非血液性毒性反应是发热性中性粒细胞减少和感染。无患者出现剂量限制性毒性。12位AML患者中有7位患者在第一个疗程后，获得完全缓解。此外，研究人员发现获得缓解和未缓解的患者的FDFT1基因甲基化水平存在显着差异（p=0.002）。本区域的预后意义在地西他滨联合化疗治疗新发的AML患儿的II期研究的数据中进一步被分析。

本研究表明阿扎胞苷联合氟达拉滨和阿糖胞苷，用于急性复发性白血病患儿，具有一定治疗效果，而且耐受性良好，需要进行进一步的验证。而甲基化生物标志物的预后意义值得进行深入评估。

原始出处：

Weili Sun，et al.A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia： a report from TACL consortium.Blood  2018  ：blood-2017-09-803809；  doi： https：//doi.org/10.1182/blood-2017-09-803809

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1411719, encodeId=86881411e1943, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506720, encodeId=29e21506e203e, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581763, encodeId=34d41581e635c, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279788, encodeId=7e862e978872, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jan 18 19:50:48 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279762, encodeId=7e0d2e9762d3, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Jan 18 19:38:32 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-20 oliver170

    #联合化疗#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1411719, encodeId=86881411e1943, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506720, encodeId=29e21506e203e, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581763, encodeId=34d41581e635c, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279788, encodeId=7e862e978872, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jan 18 19:50:48 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279762, encodeId=7e0d2e9762d3, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Jan 18 19:38:32 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-20 luwei03

    #化疗药物#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1411719, encodeId=86881411e1943, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506720, encodeId=29e21506e203e, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581763, encodeId=34d41581e635c, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279788, encodeId=7e862e978872, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jan 18 19:50:48 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279762, encodeId=7e0d2e9762d3, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Jan 18 19:38:32 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-20 12498cb5m18暂无昵称

    #化疗药#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1411719, encodeId=86881411e1943, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506720, encodeId=29e21506e203e, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581763, encodeId=34d41581e635c, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279788, encodeId=7e862e978872, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jan 18 19:50:48 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279762, encodeId=7e0d2e9762d3, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Jan 18 19:38:32 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-18 131****1460

    学习了受益匪浅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1411719, encodeId=86881411e1943, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506720, encodeId=29e21506e203e, content=<a href='/topic/show?id=7b8d3358050' target=_blank style='color:#2F92EE;'>#化疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33580, encryptionId=7b8d3358050, topicName=化疗药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5f629793993, createdName=luwei03, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581763, encodeId=34d41581e635c, content=<a href='/topic/show?id=0813335e996' target=_blank style='color:#2F92EE;'>#化疗药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33579, encryptionId=0813335e996, topicName=化疗药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=298f16872689, createdName=12498cb5m18暂无昵称, createdTime=Sat Jan 20 09:25:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279788, encodeId=7e862e978872, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Thu Jan 18 19:50:48 CST 2018, time=2018-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=279762, encodeId=7e0d2e9762d3, content=henhao, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NcXNhUvfhzd2VdicMnaLeK2Im5gKx4Ucxd8Bwu6S7RG0uILBFQx5HTW2bU4VricDYlQqN20ibASSMYAeGrZrrTpy2Q/0, createdBy=80d11516357, createdName=139****0239, createdTime=Thu Jan 18 19:38:32 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-18 139****0239

    henhao

    0

相关资讯

JCO：阿扎胞苷单药或与来那度胺或伏立诺他联合用药治疗高风险骨髓增生异常综合征或慢性单核细胞白血病

阿扎胞苷是治疗高风险骨髓增生异常综合征的标准一线用药。阿扎胞苷联合来那度胺或伏立诺他治疗的总缓解率是否优于阿扎胞苷单药尚未知。

Leuk Lymphoma：阿扎胞苷或可降低老年AML患者不良事件发生率

阿扎胞苷是一种新型表观遗传学抗肿瘤药。2017年6月，发表在《Leuk Lymphoma》的一项研究表明，急性髓细胞性白血病老年患者中，与常规治疗方案相比，阿扎胞苷可降低治疗中出现的不良事件及其相关住院的发生率。

Cancer Cell：科学家发现利用低剂量药物AZA和DAC可重编程癌细胞

阿扎胞苷(azacitidine, AZA)结构式，图片来自维基共享资源。 地西他滨(decitabine, DAC)结构式，图片来自维基共享资源。 利用细胞培养物进行实验，来自约翰霍普金斯大学基梅尔癌症研究中心的研究人员发现两种曾经被认为在人癌症治疗中毒性过强的药物的新用途。这两种药物阿扎胞苷(azacitidine, AZA)和地西他滨(decitabine, DAC)是DNA去甲基化

CLIN CANCER RES ：miRNA-DNMT1轴与与阿扎胞苷抵抗及预测高风险骨髓增生异常综合征和低原始细胞急性髓系白血病预后有关

阿扎胞苷可以抑制包括DNMT1在内的DNA甲基转移酶，目前是治疗高风险骨髓增生异常综合征（HRMDS）或低原始细胞急性髓系白血病（AML）的标准治疗方法。CLIN CANCER RES近期发表了一篇文章，作者比较了阿扎胞苷抵抗与阿扎胞苷敏感骨髓增生异常综合征细胞的miRNA表达。在体外研究不同表达的miRNA对DNMT1表达及阿扎胞苷耐药的影响。作者还评估了75例接受阿扎胞苷治疗的HRMDS或AM